Another well researched article...

"It doesn't exactly bode well, either, that the FDA previously rejected another inhalable insulin product from Pfizer (NYSE: PFE ) and that Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ) both dropped inhaled-insulin products in development. (Note that if Afrezza is approved, one or more of these companies might experience revived interest and a future competing product might be developed.)"